The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
The hot area of antibody-drug conjugates (ADCs) is getting a new player with the launch of Pheon Therapeutics, a UK-based biotech that comes armed with a sizeable cash pile and a hugely experienced senior management team.
Pheon has emerged after closing a $68m series A financing in March that was led by Brandon Capital, Forbion and...
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
